GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » US Neurosurgical Holding Inc (OTCPK:USNU) » Definitions » Return-on-Tangible-Equity

US Neurosurgical Holding (US Neurosurgical Holding) Return-on-Tangible-Equity : -255.21% (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is US Neurosurgical Holding Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. US Neurosurgical Holding's annualized net income for the quarter that ended in Mar. 2024 was $-1.25 Mil. US Neurosurgical Holding's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $0.49 Mil. Therefore, US Neurosurgical Holding's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -255.21%.

The historical rank and industry rank for US Neurosurgical Holding's Return-on-Tangible-Equity or its related term are showing as below:

USNU' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -150.87   Med: 10.1   Max: 33.36
Current: -150.87

During the past 13 years, US Neurosurgical Holding's highest Return-on-Tangible-Equity was 33.36%. The lowest was -150.87%. And the median was 10.10%.

USNU's Return-on-Tangible-Equity is ranked worse than
92.61% of 541 companies
in the Healthcare Providers & Services industry
Industry Median: 10.62 vs USNU: -150.87

US Neurosurgical Holding Return-on-Tangible-Equity Historical Data

The historical data trend for US Neurosurgical Holding's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US Neurosurgical Holding Return-on-Tangible-Equity Chart

US Neurosurgical Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.61 15.59 -29.63 -76.40 -86.62

US Neurosurgical Holding Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.46 -189.83 -80.13 -96.13 -255.21

Competitive Comparison of US Neurosurgical Holding's Return-on-Tangible-Equity

For the Medical Care Facilities subindustry, US Neurosurgical Holding's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


US Neurosurgical Holding's Return-on-Tangible-Equity Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, US Neurosurgical Holding's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where US Neurosurgical Holding's Return-on-Tangible-Equity falls into.



US Neurosurgical Holding Return-on-Tangible-Equity Calculation

US Neurosurgical Holding's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-0.816/( (1.239+0.645 )/ 2 )
=-0.816/0.942
=-86.62 %

US Neurosurgical Holding's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-1.248/( (0.645+0.333)/ 2 )
=-1.248/0.489
=-255.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


US Neurosurgical Holding  (OTCPK:USNU) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


US Neurosurgical Holding Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of US Neurosurgical Holding's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


US Neurosurgical Holding (US Neurosurgical Holding) Business Description

Traded in Other Exchanges
N/A
Address
2400 Research Boulevard, Suite 325, Rockville, MD, USA, 20850
US Neurosurgical Holding Inc operates as a holding company in United State. It is a medical services company that partners with hospitals and physicians to operate facilities utilizing artistic and inventive technologies in medical treatment and diagnosis. It is engaged in providing medical treatment and diagnosis services that include stereotactic radiosurgery centers, utilizing gamma knife technology, and holds interests in radiological treatment facilities. The company is focusing on establishing cancer centers using intensity-modulated radiation therapy. Its gamma knife is a stereotactic radiosurgical device used to treat brain tumors and other malformations of the brain without invasive surgery.
Executives
Lawrence William St director 23 ASHLAND STREET, NEWBURYPORT MA 01950-1905
William F. Leimkuhler director 43 SALEM STRAITS RD, DARIEN CT 06820
Merriman Charles H Iii director
Alan Gold director, 10 percent owner, officer: President & Chairman 2400 RESEARCH BLVD, SUITE 325, ROCKVILLE MD 20850
Stanley S Shuman 10 percent owner C/O RIPPLEWOOD HOLDINGS LLC, ONE ROCKERFELLER PLAZA, NEW YORK NY 10020
Allen & Co Inc 10 percent owner 711 FIFTH AVENUE, NEW YORK NY 10022

US Neurosurgical Holding (US Neurosurgical Holding) Headlines

No Headlines